A Biogen facility in Cambridge, Massachusetts.
Brian Snyder | Reuters
Investors are underestimating a new Alzheimer's drug from Biogen and some of the company's other key businesses, according to Wells Fargo.
Investors are underestimating a new Alzheimer's drug from Biogen and some of the company's other key businesses, according to Wells Fargo.